ESR1 and colorectal carcinoma: Bazedoxifene, the third‐generation of selective estrogen receptor modulator, also a novel IL‐6/glycoprotein 130 (GP130) target inhibitor, improved the anticancer effect of 5‐FU in CRC via impeding the IL‐6/GP130 signaling pathway and the phosphorylation of the downstream effectors such as AKT, ERK, and STAT3, suggesting that the block of IL‐6/GP130 might reverse chemoresistance in CRC.23